Peptide therapy for anti-CD4 autoimmunity in HIV-1 infection

Toward the development of an autoimmune animal model

R. Abulafia-Lapid, M. Afentoulis, Arthur Vandenbark

Research output: Contribution to journalArticle

Abstract

Aiming to develop an animal model for anti-CD4 autoimmunity reflective of that observed in HIV-1 patients, we injected the selected peptides p1, p28 and p29 as the major immunogenic epitopes into HLA-DR4 and human CD4 transgenic DBA/16J mice, as well as into C57BL/6 and DBA mice. We document a decrease of CD4+ cells in peripheral blood and spleen after immunization with the human CD4-p28 immunogenic peptide of transgenic mice expressing human CD4, human HLA class II and mouse class II I-Aq (HLA-DR4-huCD4-I-Aq+); however, no decrease of CD4 cells was found in transgenic HLA-DR4-huCD4-I-Aq- mice or in control C57BL/6 and DBA immunized mice. Overall, the consistency of CD4 reduction and immunological recognition of p28 peptide favors the HLA-DR4-huCD4-I-Aq+ mouse as the most promising autoimmune mouse model.

Original languageEnglish (US)
Pages (from-to)3475-3480
Number of pages6
JournalVaccine
Volume27
Issue number25-26
DOIs
StatePublished - May 26 2009

Fingerprint

HLA-DR4 Antigen
autoimmunity
Human immunodeficiency virus 1
Autoimmunity
Inbred DBA Mouse
HIV Infections
HIV-1
Animal Models
animal models
peptides
therapeutics
Peptides
mice
infection
Transgenic Mice
genetically modified organisms
Therapeutics
Inbred C57BL Mouse
Epitopes
Immunization

Keywords

  • Anti-CD4 autoimmunity
  • HIV-1
  • Transgenic mice

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Peptide therapy for anti-CD4 autoimmunity in HIV-1 infection : Toward the development of an autoimmune animal model. / Abulafia-Lapid, R.; Afentoulis, M.; Vandenbark, Arthur.

In: Vaccine, Vol. 27, No. 25-26, 26.05.2009, p. 3475-3480.

Research output: Contribution to journalArticle

@article{4f0f32b551a640b3ba6a7dbcd08da7a7,
title = "Peptide therapy for anti-CD4 autoimmunity in HIV-1 infection: Toward the development of an autoimmune animal model",
abstract = "Aiming to develop an animal model for anti-CD4 autoimmunity reflective of that observed in HIV-1 patients, we injected the selected peptides p1, p28 and p29 as the major immunogenic epitopes into HLA-DR4 and human CD4 transgenic DBA/16J mice, as well as into C57BL/6 and DBA mice. We document a decrease of CD4+ cells in peripheral blood and spleen after immunization with the human CD4-p28 immunogenic peptide of transgenic mice expressing human CD4, human HLA class II and mouse class II I-Aq (HLA-DR4-huCD4-I-Aq+); however, no decrease of CD4 cells was found in transgenic HLA-DR4-huCD4-I-Aq- mice or in control C57BL/6 and DBA immunized mice. Overall, the consistency of CD4 reduction and immunological recognition of p28 peptide favors the HLA-DR4-huCD4-I-Aq+ mouse as the most promising autoimmune mouse model.",
keywords = "Anti-CD4 autoimmunity, HIV-1, Transgenic mice",
author = "R. Abulafia-Lapid and M. Afentoulis and Arthur Vandenbark",
year = "2009",
month = "5",
day = "26",
doi = "10.1016/j.vaccine.2009.01.049",
language = "English (US)",
volume = "27",
pages = "3475--3480",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "25-26",

}

TY - JOUR

T1 - Peptide therapy for anti-CD4 autoimmunity in HIV-1 infection

T2 - Toward the development of an autoimmune animal model

AU - Abulafia-Lapid, R.

AU - Afentoulis, M.

AU - Vandenbark, Arthur

PY - 2009/5/26

Y1 - 2009/5/26

N2 - Aiming to develop an animal model for anti-CD4 autoimmunity reflective of that observed in HIV-1 patients, we injected the selected peptides p1, p28 and p29 as the major immunogenic epitopes into HLA-DR4 and human CD4 transgenic DBA/16J mice, as well as into C57BL/6 and DBA mice. We document a decrease of CD4+ cells in peripheral blood and spleen after immunization with the human CD4-p28 immunogenic peptide of transgenic mice expressing human CD4, human HLA class II and mouse class II I-Aq (HLA-DR4-huCD4-I-Aq+); however, no decrease of CD4 cells was found in transgenic HLA-DR4-huCD4-I-Aq- mice or in control C57BL/6 and DBA immunized mice. Overall, the consistency of CD4 reduction and immunological recognition of p28 peptide favors the HLA-DR4-huCD4-I-Aq+ mouse as the most promising autoimmune mouse model.

AB - Aiming to develop an animal model for anti-CD4 autoimmunity reflective of that observed in HIV-1 patients, we injected the selected peptides p1, p28 and p29 as the major immunogenic epitopes into HLA-DR4 and human CD4 transgenic DBA/16J mice, as well as into C57BL/6 and DBA mice. We document a decrease of CD4+ cells in peripheral blood and spleen after immunization with the human CD4-p28 immunogenic peptide of transgenic mice expressing human CD4, human HLA class II and mouse class II I-Aq (HLA-DR4-huCD4-I-Aq+); however, no decrease of CD4 cells was found in transgenic HLA-DR4-huCD4-I-Aq- mice or in control C57BL/6 and DBA immunized mice. Overall, the consistency of CD4 reduction and immunological recognition of p28 peptide favors the HLA-DR4-huCD4-I-Aq+ mouse as the most promising autoimmune mouse model.

KW - Anti-CD4 autoimmunity

KW - HIV-1

KW - Transgenic mice

UR - http://www.scopus.com/inward/record.url?scp=67349185880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349185880&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.01.049

DO - 10.1016/j.vaccine.2009.01.049

M3 - Article

VL - 27

SP - 3475

EP - 3480

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 25-26

ER -